MBG453 is an anti-TIM-3 mAb for which the efficacy and safety have been evaluated in first clinical trials as a single agent or in combination with PDR001 (anti-PD-1 mAb) in advanced malignancy patients (NCT02608268). Here, PDCD1 is linked to cancer.